Summary

The stem cell therapy market is projected to reach USD 3.65 billion by 2035 from USD 0.48 billion in 2026, at a CAGR of 25.3% from 2026 to 2035. The market is driven by the expanding pipeline of stem cell-based therapies, increasing demand for regenerative treatments, and growth in advanced modalities such as iPSC-derived therapies and allogeneic cell products. Market estimates indicate robust expansion through 2035, supported by technological advancements in cell processing and manufacturing and rising clinical adoption of approved stem cell therapies. However, high manufacturing and treatment costs, complex regulatory pathways across regions, scalability challenges from bench to commercial manufacturing, and the need for specialized infrastructure and expertise are expected to restrain broader market growth.

“The induced pluripotent stem cell (iPSC) segment is projected to grow at the highest CAGR in the stem cell therapy market over the forecast period.”
Based on cell source, the stem cell therapy market is broadly segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, induced pluripotent stem cells, embryonic stem cells, tissue-specific stem cells, and other cell sources. The induced pluripotent stem cell (iPSC) segment is expected to grow at the highest CAGR in the stem cell therapy market because it is moving from a high-potential research platform toward early commercial validation, while still starting from a relatively low revenue base. iPSCs provide a renewable and scalable cell source that can be differentiated into multiple therapeutic cell types, including dopaminergic neurons, cardiomyocytes, retinal cells, pancreatic beta-like cells, and other tissue-specific cells, making them attractive for large unmet-need indications such as Parkinson’s disease, heart failure, diabetes, retinal disorders, and other degenerative diseases.
“Allogeneic stem cell therapy accounted for the largest share of the stem cell therapy market, by type, in 2025.”
Based on type, the global stem cell therapy market is segmented into allogeneic and autologous stem cell therapies. The allogeneic stem cell therapy segment accounted for the largest share of the stem cell therapy market in 2025, due to its scalability, off-the-shelf availability, and cost advantages in commercial manufacturing. These therapies enable standardized production and broader patient access essential for clinical and commercial applications. Additionally, the expanding pipeline of allogeneic cell therapy candidates, increasing regulatory approvals, and growing commercial-scale manufacturing activities continue to strengthen the segment’s leading market position globally.
“Europe is projected to grow at the highest CAGR in the stem cell therapy market from 2026 to 2035.”
The stem cell therapy market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, Europe is projected to be the fastest-growing region in the stem cell therapy market due to its strong regulatory framework for advanced therapy medicinal products, expanding transplant and cell therapy infrastructure, high clinical trial activity, and rising investment in scalable ATMP manufacturing. The EMA classifies substantially manipulated or non-homologous stem-cell products as ATMPs and has a dedicated Committee for Advanced Therapies, creating a clear pathway for stem cell-based product assessment, scientific advice, and market authorization.
The primary interviews conducted for this report can be categorized as follows:
・By Respondent: Supply Side (70%) and Demand Side (30%)
・By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
・By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)
List of Companies Profiled in the Report
Key players in the global stem cell therapy market include Vericel Corporation (US), Mesoblast (Australia), MEDIPOST (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Anterogen Co., Ltd. (South Korea), CorestemChemon Inc. / Corestem, Inc. (South Korea), Vertex Pharmaceuticals (US), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), Stempeutics Research Pvt. Ltd. (India), Cipla Limited (India), Bayer AG (Germany), Aspen Neuroscience (US), Longeveron Inc. (US), and Smith+Nephew (UK).
Research Coverage
This research report categorizes the stem cell therapy market by Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Placenta/Umbilical Cord-Derived Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Tissue-Specific Stem Cells, Other Cell Sources), Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Therapeutic Application (Musculoskeletal Disorders, Wounds & Surgeries, Inflammatory & Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, Diabetes & Metabolic Diseases, Other Therapeutic Applications), End User (Hospitals, Specialty / Stem Cell Clinics, Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa)
The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the stem cell therapy market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the stem cell therapy market. This report covers competitive analysis of top players and upcoming startups in the stem cell therapy market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
o Analysis of key drivers (rising regulatory approvals are validating stem cell therapy as a viable commercial treatment class, high unmet needs in rare and chronic diseases are driving demand for curative therapies, gene-modified HSPC therapies are creating a high-value segment in the stem cell therapy market, allogeneic and off-the-shelf approaches are improving scalability over autologous therapies), restraints (high therapy price and uncertain reimbursement remain the largest restraints on market adoption, manufacturing complexity and high cost of goods limit scalability and margins, inconsistent clinical evidence in some regenerative indications reduces payer and physician confidence, regulatory heterogeneity across countries complicates global commercialization.), opportunities (iPSC-derived therapies offer long-term opportunities for scalable cell replacement, allogeneic MSC and progenitor-cell platforms can expand access beyond individualized therapy, expansion into neurological, cardiovascular, metabolic, and ocular diseases can broaden market potential, Gene-modified HSPC therapies can expand into younger patients, additional hemoglobinopathies, immune diseases, and metabolic diseases), and challenges (potency testing and product characterization challenges, demonstrating clear clinical efficacy is difficult in heterogeneous regenerative indications, manufacturing comparability after process changes can delay scale-up and approval, patient referral, eligibility, and treatment readiness can slow real-world uptake
o Product Development/Innovation: Detailed insights into upcoming technologies and research & development activities in the global stem cell therapy market
o Market Development: Comprehensive information about lucrative markets (the report analyzes the market across varied regions)
o Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global stem cell therapy market
o Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players (a detailed analysis of the key industry players has been carried out to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investments & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the global stem cell therapy market)

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS SEGMENTATION AND REGIONAL SCOPE 31
1.4 INCLUSIONS & EXCLUSIONS 32
1.4.1 YEARS CONSIDERED 32
1.4.2 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHNAGES 33
2 EXECUTIVE SUMMARY 35
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 38
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40
3 PREMIUM INSIGHTS 41
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN STEM CELL THERAPY MARKET 41
3.2 STEM CELL THERAPY MARKET, BY TYPE AND REGION 42
3.3 STEM CELL THERAPY MARKET, BY COUNTRY 42
3.4 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2026 VS 2035 43
4 MARKET OVERVIEW 44
4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Rising regulatory approvals validating stem cell therapies 45
4.2.1.2 Unmet needs in rare and chronic diseases driving demand for curative therapies 46
4.2.1.3 Allogeneic and off-the-shelf approaches improving scalability
over autologous therapies 46
4.2.2 RESTRAINTS 46
4.2.2.1 High therapy price and uncertain reimbursement limiting adoption 46
4.2.2.2 Manufacturing complexity and high cost of goods limiting
scalability and margins 47
4.2.2.3 Inconsistent clinical evidence reducing payer and physician confidence 47
4.2.2.4 Regulatory inconsistency across countries complicating
global commercialization 48
4.2.3 OPPORTUNITY 48
4.2.3.1 iPSC-derived therapies offering long-term opportunities for
scalable cell replacement 48
4.2.3.2 Allogeneic MSC and progenitor-cell platforms can support expansion beyond personalized treatment models 48
4.2.3.3 Expansion into neurological, cardiovascular, and metabolic diseases 49
4.2.4 CHALLENGES 49
4.2.4.1 Potency testing and product characterization challenges 49
4.2.4.2 Difficulty in demonstrating clear clinical efficacy in heterogeneous regenerative indications 49
4.2.4.3 Manufacturing comparability challenges following process changes may delay scale-up and regulatory approval 49
4.3 UNMET NEEDS AND WHITE SPACES 50
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51
5 INDUSTRY TRENDS 52
5.1 PORTER'S FIVE FORCES ANALYSIS 52
5.1.1 THREAT OF NEW ENTRANTS 53
5.1.2 THREAT OF SUBSTITUTES 53
5.1.3 BARGAINING POWER OF BUYERS 53
5.1.4 BARGAINING POWER OF SUPPLIERS 53
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 INTRODUCTION 54
5.2.2 GDP TRENDS AND FORECAST 55
5.2.3 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55
5.2.4 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 58
5.5 PRICING ANALYSIS 59
5.5.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 59
5.5.2 INDICATIVE SELLING PRICE, BY REGION 60
5.6 KEY CONFERENCES & EVENTS 61
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 62
5.8 INVESTMENT/FUNDING ACTIVITY 62
5.9 CASE STUDY ANALYSIS 63
5.10 IMPACT OF 2025 US TARIFF - STEM CELL THERAPY MARKET 64
5.10.1 INTRODUCTION 64
5.10.2 KEY TARIFF RATES 64
5.10.3 PRICE IMPACT ANALYSIS 65
5.10.4 IMPACT ON COUNTRY/REGION 66
5.10.4.1 North America 66
5.10.4.2 Europe 66
5.10.4.3 Asia Pacific 67
5.10.5 IMPACT ON END-USE INDUSTRIES 67
5.10.5.1 Hospitals 67
5.10.5.2 Specialty/Stem cell clinics 68
5.10.5.3 Other end users 68
5.11 SUPPLY CHAIN ANALYSIS 68
5.12 KEY STEM CELL THERAPY MANUFACTURING CAPACITY ADDITIONS 70
5.12.1 KEY CDMO CAPACITY ADDITIONS 70
5.12.2 KEY SPONSOR CAPACITY ADDITIONS 70
5.12.3 GLOBAL KEY STEM CELL THERAPY PRODUCT SALES 72
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
INNOVATIONS, AND FUTURE APPLICATIONS 73
6.1 TECHNOLOGY ANALYSIS 73
6.1.1 KEY TECHNOLOGIES 73
6.1.1.1 Bioreactor systems 73
6.1.1.2 Cell expansion & differentiation platforms 73
6.1.2 ADJACENT TECHNOLOGIES 73
6.1.2.1 Reprogramming & gene engineering tools 73
6.1.2.2 Downstream processing technologies 73
6.1.3 COMPLEMENTARY TECHNOLOGIES 74
6.1.3.1 Advanced cell culture consumables 74
6.1.3.2 Automation and robotics 74
6.2 TECHNOLOGY/PRODUCT ROADMAP 74
6.3 PIPELINE ANALYSIS 74
6.4 FUTURE APPLICATIONS 77
6.5 IMPACT OF AI/GEN AI ON STEM CELL THERAPY MARKET 77
6.5.1 TOP USE CASES AND MARKET POTENTIAL 78
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN STEM CELL THERAPY MARKET 78
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 78
6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN STEM CELL
THERAPY MARKET 79
6.6 SUCCESS STORIES AND REAL WORLD APPLICATIONS 80
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 81
7.1 REGIONAL REGULATIONS AND COMPLIANCE 81
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 81
7.1.2 REGULATORY FRAMEWORK 84
7.1.3 INDUSTRY STANDARDS 84
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 85
7.3 CERTIFICATIONS, LABELING & ECO-STANDARDS 85
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88
8.1 DECISION-MAKING PROCESS 88
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 89
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
8.2.2 KEY BUYING CRITERIA, BY END USER 89
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 91
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91
8.5 MARKET PROFITABILITY 92
9 STEM CELL THERAPY MARKET BY CELL SOURCE 93
9.1 INTRODUCTION 94
9.2 ADIPOSE TISSUE-DERIVED MSCS 94
9.2.1 GROWING ADOPTION OF ADIPOSE-DERIVED MSC THERAPIES IN RECONSTRUCTIVE SURGERY AND AESTHETIC MEDICINE DRIVING MARKET 94
9.3 BONE MARROW-DERIVED MSCS 97
9.3.1 ACCELERATING REGULATORY MILESTONES AND EXPANDING INDICATIONS FOR BONE MARROW-DERIVED MSC THERAPIES DRIVING MARKET GROWTH 97
9.4 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS 100
9.4.1 EXPANDING CORD BLOOD BANKING INFRASTRUCTURE AND ALLOGENEIC PRODUCT DEVELOPMENT FUELING SEGMENT GROWTH 100
9.5 INDUCED PLURIPOTENT STEM CELLS (IPSCS) 102
9.5.1 BREAKTHROUGH CLINICAL PROGRAMS AND NEXT-GENERATION MANUFACTURING PLATFORMS POSITIONING IPSCS AS TRANSFORMATIVE CELL SOURCE 102
9.6 EMBRYONIC STEM CELLS (ESCS) 105
9.6.1 LANDMARK REGULATORY APPROVALS AND CLINICAL VALIDATION OF
ESC-DERIVED ISLET CELL THERAPIES CATALYZING GROWTH 105
9.7 TISSUE-SPECIFIC STEM CELLS 108
9.7.1 ESTABLISHED COMMERCIAL PRODUCTS AND EXPANDING CLINICAL APPLICATIONS FUELING MARKET GROWTH 108
9.8 OTHER CELL SOURCES 110
10 STEM CELL THERAPY MARKET BY TYPE 113
10.1 INTRODUCTION 114
10.2 ALLOGENEIC STEM CELL THERAPY 114
10.2.1 SCALABLE OFF-THE-SHELF MANUFACTURING AND EXPANDING CLINICAL PIPELINES DRIVING RAPID GROWTH 114
10.3 AUTOLOGOUS STEM CELL THERAPY 117
10.3.1 ESTABLISHED COMMERCIAL PRODUCTS AND PATIENT-SPECIFIC IMMUNOLOGICAL ADVANTAGES TO SUSTAIN STEADY GROWTH 117
11 STEM CELL THERAPY MARKET BY THERAPEUTIC APPLICATION 120
11.1 INTRODUCTION 121
11.2 MUSCULOSKELETAL DISORDERS 121
11.2.1 RISING GLOBAL PREVALENCE OF OSTEOARTHRITIS AND GROWING ADOPTION OF CELL-BASED CARTILAGE REPAIR THERAPIES DRIVING SEGMENT GROWTH 121
11.3 WOUNDS & SURGERIES 124
11.3.1 EXPANDING APPLICATIONS OF STEM CELL THERAPIES IN WOUND HEALING, BURN TREATMENT, AND SURGICAL RECONSTRUCTION SUPPORTING SEGMENT GROWTH 124
11.4 INFLAMMATORY & AUTOIMMUNE DISEASES 127
11.4.1 EXPANDING CLINICAL VALIDATION OF MSC IMMUNOMODULATORY PROPERTIES AND FDA APPROVAL OF RYONCIL FOR GVHD DRIVING GROWTH 127
11.5 CARDIOVASCULAR DISEASES 129
11.5.1 ADVANCING LATE-STAGE CLINICAL PROGRAMS AND GROWING EVIDENCE FOR MSC-MEDIATED CARDIAC REPAIR SUPPORTING MARKET GROWTH 129
11.6 NEUROLOGICAL DISORDERS 132
11.6.1 BREAKTHROUGH IPSC-DERIVED NEURONAL THERAPIES AND EXPANDING CLINICAL PROGRAMS FOR NEURODEGENERATIVE CONDITIONS DRIVING SEGMENTAL GROWTH 132
11.7 DIABETES & METABOLIC DISEASES 135
11.7.1 TRANSFORMATIVE POTENTIAL OF ESC-DERIVED ISLET CELL THERAPIES FOR TYPE 1 DIABETES FUELING RAPID MARKET GROWTH 135
11.8 OTHER THERAPEUTIC APPLICATIONS 137
12 STEM CELL THERAPY MARKET, BY END USER 140
12.1 INTRODUCTION 141
12.2 HOSPITALS 141
12.2.1 ADVANCED TRANSPLANT INFRASTRUCTURE AND CONCENTRATION OF REGULATORY-APPROVED STEM CELL THERAPY ADMINISTRATION
DRIVING GROWTH 141
12.3 SPECIALTY/STEM CELL CLINICS 144
12.3.1 GROWING NUMBER OF DEDICATED REGENERATIVE MEDICINE CENTERS
AND EXPANDING AUTOLOGOUS MSC TREATMENT OFFERINGS DRIVING SEGMENTAL GROWTH 144
12.4 OTHER END USERS 146
12.4.1 AMBULATORY SURGICAL CENTERS, ACADEMIC RESEARCH INSTITUTES,
AND CELL BANKS EXPANDING STEM CELL THERAPY DELIVERY ECOSYSTEM 146
13 STEM CELL THERAPY MARKET, BY REGION 150
13.1 INTRODUCTION 151
13.2 NORTH AMERICA 151
13.2.1 US 154
13.2.2 CANADA 155
 
13.3 EUROPE 157
13.3.1 GERMANY 160
13.3.2 UK 161
13.3.3 FRANCE 163
13.3.4 ITALY 164
13.3.5 SPAIN 166
13.3.6 REST OF EUROPE 167
13.4 ASIA PACIFIC 169
13.4.1 CHINA 171
13.4.2 JAPAN 172
13.4.3 INDIA 174
13.4.4 SOUTH KOREA 175
13.4.5 AUSTRALIA 177
13.4.6 REST OF ASIA PACIFIC 178
13.5 LATIN AMERICA 180
13.5.1 BRAZIL 182
13.5.2 MEXICO 183
13.5.3 REST OF LATIN AMERICA 185
13.6 MIDDLE EAST 186
13.6.1 GCC COUNTRIES 188
13.6.1.1 Saudi Arabia 190
13.6.1.2 UAE 191
13.6.1.3 Rest of GCC Countries 193
13.6.2 REST OF MIDDLE EAST 194
13.7 AFRICA 196
14 COMPETITIVE LANDSCAPE 198
14.1 INTRODUCTION 198
14.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 198
14.3 REVENUE ANALYSIS, 2023–2025 199
14.4 MARKET SHARE ANALYSIS, 2025 201
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 203
14.5.1 STARS 203
14.5.2 EMERGING LEADERS 203
14.5.3 PERVASIVE PLAYERS 203
14.5.4 PARTICIPANTS 203
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 205
14.5.5.1 Company footprint 205
14.5.5.2 Region footprint 206
14.5.5.3 Cell source footprint 207
14.5.5.4 Type footprint 208
14.5.5.5 Therapeutic application footprint 209
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 210
14.6.1 PROGRESSIVE COMPANIES 210
14.6.2 RESPONSIVE COMPANIES 210
14.6.3 DYNAMIC COMPANIES 210
14.6.4 STARTING BLOCKS 210
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 212
14.6.5.1 List of key startups/SMEs 212
14.6.5.2 Competitive benchmarking of key startups/SMEs 213
14.7 COMPANY VALUATION & FINANCIAL METRICS 213
14.7.1 FINANCIAL METRICS 214
14.7.2 COMPANY VALUATION 214
14.8 BRAND/PRODUCT COMPARISON 215
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 215
14.9 COMPETITIVE SCENARIO 216
14.9.1 PRODUCT LAUNCHES 216
14.9.2 DEALS 217
15 COMPANY PROFILES 218
15.1 KEY PLAYERS 218
15.1.1 VERICEL CORPORATION 218
15.1.1.1 Business overview 218
15.1.1.2 Products offered 219
15.1.1.3 Recent developments 220
15.1.1.3.1 Product Approval 220
15.1.1.4 MnM view 220
15.1.1.4.1 Key strengths 220
15.1.1.4.2 Strategic choices 220
15.1.1.4.3 Weaknesses & competitive threats 220
15.1.2 MESOBLAST 221
15.1.2.1 Business overview 221
15.1.2.2 Products offered 222
15.1.2.3 Recent developments 223
15.1.2.3.1 Product approval 223
15.1.2.4 MnM view 223
15.1.2.4.1 Key strengths 223
15.1.2.4.2 Strategic choices 223
15.1.2.4.3 Weaknesses & competitive threats 224
15.1.3 JCR PHARMACEUTICALS CO., LTD. 225
15.1.3.1 Business overview 225
15.1.3.2 Products offered 226
15.1.3.3 Product pipeline 227
 
15.1.3.4 MnM view 227
15.1.3.4.1 Key strengths 227
15.1.3.4.2 Strategic choices 227
15.1.3.4.3 Weaknesses & competitive threats 227
15.1.4 MEDIPOST 228
15.1.4.1 Business overview 228
15.1.4.2 Products offered 229
15.1.4.3 Recent developments 229
15.1.4.3.1 Deals 229
15.1.4.3.2 OTHER DEVELOPMENTS 230
15.1.4.4 MnM view 230
15.1.4.4.1 Key strengths 230
15.1.4.4.2 Strategic choices 230
15.1.4.4.3 Weaknesses & competitive threats 231
15.1.5 CO.DON GMBH 232
15.1.5.1 Business overview 232
15.1.5.2 Products offered 232
15.1.5.3 MnM view 233
15.1.5.3.1 Key strengths 233
15.1.5.3.2 Strategic choices 233
15.1.5.3.3 Weaknesses & competitive threats 233
15.1.6 SMITH+NEPHEW 234
15.1.6.1 Business overview 234
15.1.6.2 Products offered 235
15.1.7 ANTEROGEN CO., LTD. 236
15.1.7.1 Business overview 236
15.1.7.2 Products offered 236
15.1.8 CORESTEMCHEMON INC. 237
15.1.8.1 Business overview 237
15.1.8.2 Products offered 238
15.1.9 VERTEX PHARMACEUTICALS INCORPORATED 239
15.1.9.1 Business overview 239
15.1.9.2 Products offered 240
15.1.9.2.1 Other developments 240
15.1.10 PHARMICELL CO., LTD 241
15.1.10.1 Business overview 241
15.1.10.2 Products offered 241
15.1.10.3 Recent developments 242
15.1.10.3.1 Deals 242
15.1.11 HOLOSTEM TERAPIE AVANZATE SRL 243
15.1.11.1 Business overview 243
15.1.11.2 Products offered 243
15.1.12 STEMPEUTICS RESEARCH PVT LTD. 244
15.1.12.1 Business overview 244
15.1.12.2 Products offered 244
15.1.12.3 Recent developments 245
15.1.12.3.1 Deals 245
15.1.13 CIPLA LIMITED 246
15.1.13.1 Business overview 246
15.1.13.2 Products offered 247
15.1.13.3 Recent developments 248
15.1.13.3.1 Product Launch 248
15.1.13.3.2 Deals 248
15.1.14 BAYER AG 249
15.1.14.1 Business overview 249
15.1.14.2 Products offered 250
15.1.14.2.1 OTHER DEVELOPMENTS 251
15.1.15 ASPEN NEUROSCIENCE 252
15.1.15.1 Business overview 252
15.1.15.2 Products offered 252
15.1.15.2.1 Other developments 252
15.1.16 LONGEVERON 253
15.1.16.1 Business overview 253
15.1.16.2 Products offered 254
15.1.16.2.1 Other developments 254
15.2 OTHER PLAYERS 255
15.2.1 ATHERSYS, INC. 255
15.2.2 BIORESTORATIVE THERAPIES, INC. 255
15.2.3 KANGSTEM BIOTECH CO., LTD. 256
15.2.4 HOPE BIOSCIENCES 256
15.2.5 CELLULAR BIOMEDICINE GROUP 257
15.2.6 PERSONALIZED STEM CELLS 257
15.2.7 CHIESI FARMACEUTICI S.P.A. 258
15.2.8 CELL TECH PHARMED 258
15.2.9 SUMITOMO PHARMA 259
15.2.10 CYNATA THERAPEUTICS 260
16 RESEARCH METHODOLOGY 261
16.1 RESEARCH DATA 261
16.1.1 SECONDARY DATA 262
16.1.2 PRIMARY DATA 262
16.2 MARKET ESTIMATION METHODOLOGY 264
16.2.1 MARKET SIZE ESTIMATION 264
16.2.2 INSIGHTS OF PRIMARY EXPERTS 266
16.2.3 TOP-DOWN APPROACH 267
16.3 MARKET GROWTH RATE PROJECTIONS 268
16.4 MARKET BREAKDOWN AND DATA TRIANGULATION 270
16.5 RESEARCH ASSUMPTIONS 271
16.6 RESEARCH LIMITATIONS 271
16.7 RISK ASSESSMENT 272
17 APPENDIX 273
17.1 DISCUSSION GUIDE 273
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
17.3 CUSTOMIZATION OPTIONS 279
17.4 RELATED REPORTS 279
17.5 AUTHOR DETAILS 280